Dr Ben Kong

Conjoint Senior Lecturer

BSc (Hons I), MBBS (USyd), Grad Cert Drug Development (91ɫ��Ƭ), PhD (Usyd), FRACP

Medicine & Health

School of Clinical Medicine

Dr Ben Kong is a Senior Research Fellow in Poor Outcomes Cancers within SPHERE Cancer Clinical Academic Group. He is appointed as a Medical Oncologist at Prince of Wales Hospital where he treats patients with lung and head and neck cancers. He is also a Research Fellow at the NHMRC Clinical Trials Centre where he is responsible for the design and conduct of investigator-initiated cancer clinical trials with the Co-operative Group for Neuro-Oncology (COGNO).��

Prior to joining SPHERE, he completed his PhD in Cancer Immunology within the Dendritic Cell Research Group at the ANZAC Research Institute with Professor Derek Hart, characterising circulating dendritic cells in patients with glioblastoma and developing pre-clinical studies examining combination immune checkpoint inhibitors with dendritic cell vaccination using CMV as a model tumour antigen. He is currently leading clinical research in lung cancer and brain metastases with the aim of extending this into translational research in cancers affecting the central nervous system to develop more effective treatments in brain cancer.��

Ben is a member of the 91ɫ��Ƭ Australian Centre for��NanoMedicine��and a mentor with Health10x and Biotech Accelerator Programmes.

��

Phone

+61 2 9382 5111

E-mail

benjamin.kong@unsw.edu.au

Location

Level 4, Lowy Cancer Research Centre

Journal articles | 2026

Alexander M; Itchins M; Felthun J; Nagrial A; Brown LJ; O'Byrne K; Mersiades AJ; Hughes BGM; Warburton L; Kong BY; Moore M; Blinman P; Bowyer S; Clay T; Spelman T; Pavlakis N; Solomon BJ; Kao S, 2026, 'Impact of PD-L1 on first-line osimertinib outcomes in EGFR-mutant NSCLC: real-world data from the AURORA25 study and meta-analysis', Lung Cancer, 211,

Journal articles | 2026

Itchins M; Alexander M; Kao S; Nagrial A; Brown LJ; Bowyer S; Parakh S; Moore M; Kong BY; Yeo N; Hughes BGM; Arulananda S; Chin V; Warburton L; Khoo T; Mersiades AJ; Leigh L; Rogers J; Pavlakis N; Solomon BJ, 2026, 'Real-world treatment sequencing and survival in ROS1-Rearranged NSCLC across evolving treatment eras: Findings from the AURORA multi-centre registry (AURORA-ROS1)', Lung Cancer, 218,

Journal articles | 2026

Tan AC; Kong BY; Li MSC, 2026, 'Rare ALK Fusions in NSCLC—Expanding the Boundaries of Precision Oncology', Jto Clinical and Research Reports, 7,

Journal articles | 2026

Valerie IC; Aly F; Niknam Shirvan G; Alam FI; Johnston M; Kong BY; Findlay M; Holloway L; Kennedy G, 2026, 'Bridging Clinical Observational Research and Data Standards in Head and Neck Cancer Care: Scoping Review and Mapping of Clinical Data Elements', JCO Clinical Cancer Informatics, 10, pp. e2600177,

Journal articles | 2025

McParland K; Koh ES; Kong B; Sim HW; Thavaneswaran S; Yip S; Barnes EH; Ballinger ML; Thomas DM; De Abreu Lourenco R; Simes J; Sebastian L; Wheeler PJ; Spyridopoulos D; Hawkins C; Pitz M; O'Callaghan C; Gan HK, 2025, 'Low & Anaplastic Grade Glioma Umbrella Study of MOlecular Guided TherapieS (LUMOS-2): study protocol for a phase 2, prospective, multicentre, open-label, multiarm, biomarker-directed, signal-seeking, umbrella, clinical trial for recurrent IDH mutant, grade 2/3 glioma', BMJ Open, 15,

Journal articles | 2025

Shahnam A; Davis A; Brown LJ; Sullivan I; Lin K; Ng C; Yeo N; Kong BY; Khoo T; Warburton L; Da Silva IP; Mullally W; Xu W; O'Byrne K; Bray V; Pal A; Mersaides A; Itchins M; Arulananda S; Nagrial A; Kao S; Alexander M; Lee CK; Solomon B; John T, 2025, 'Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations', Lung Cancer, 201,

Journal articles | 2025

Yeo N; Johnston F; Fay L; Lilburn P; Kennedy D; Barrett H; Shand A; Kidson-Gerber G; Tang M; Challis D; Kong BY, 2025, 'Beating the Odds: A Successful Pregnancy in a Patient With ALK-Rearranged Lung Cancer on Alectinib', Case Reports in Medicine, 2025,

Journal articles | 2025

Yuile A; Satgunaseelan L; Alexander KL; Thavaneswaran S; Sim HW; Krasovitsky M; Kong BY; Miller S; Buckland ME; Lee M; Wei G; Kastelan M; Wong M; Wilson I; Bayly A; Varikatt W; Lwin Z; Turner C; Back MF; Pavlakis N; Wei JQ; Hudson A; Chan DL; Wheeler HR; Lee A, 2025, 'Clinical outcomes and management of CDKN2A/B homozygously deleted IDH-mutant astrocytomas—a cohort study and patterns of care survey', Neuro Oncology Practice, 12, pp. 787 - 796,

Journal articles | 2024

Alexander M; Rogers J; Parakh S; Mitchell P; Clay TD; Kao S; Hughes BGM; Itchins M; Kong BY; Pavlakis N; Solomon BJ; John T, 2024, 'Lurbinectedin in small cell lung cancer: real-world experience of a multicentre national early access programme', Internal Medicine Journal, 54, pp. 1087 - 1096,

Journal articles | 2024

Brown LJ; Khou V; Brown C; Alexander M; Jayamanne D; Wei J; Gray L; Chan WY; Smith S; Harden S; Mersiades A; Warburton L; Itchins M; Lee JH; Pavlakis N; Clarke SJ; Boyer M; Nagrial A; Hau E; Pires da Silva I; Kao S; Kong BY, 2024, 'First-line chemoimmunotherapy and immunotherapy in patients with non-small cell lung cancer and brain metastases: a registry study', Frontiers in Oncology, 14,

Journal articles | 2023

Agar MR; Nowak AK; Hovey EJ; Barnes EH; Simes J; Vardy JL; Wheeler HR; Kong BY; Leonard R; Hall M; Tim E; Spyridopoulos D; Sim HW; Lwin Z; Dowling A; Harrup R; Jennens R; Kichenadasse G; Dunlop T; Gzell C; Koh ES, 2023, 'Acetazolamide versus placebo for cerebral oedema requiring dexamethasone in recurrent and/or progressive high-grade glioma: phase II randomised placebo-controlled double-blind study', BMJ Supportive and Palliative Care, 13, pp. 354 - 362,

Journal articles | 2023

Sim H-W; Wachsmuth L; Barnes EH; Yip S; Koh E-S; Hall M; Jennens R; Ashley DM; Verhaak RG; Heimberger AB; Rosenthal MA; Hovey EJ; Ellingson BM; Tognela A; Gan HK; Wheeler H; Back M; McDonald KL; Long A; Cuff K; Begbie S; Gedye C; Mislang A; Le H; Johnson MO; Kong BY; Simes JR; Lwin Z; Khasraw M, 2023, 'NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma', Neuro-Oncology Advances, 5, pp. vdad124,

Journal articles | 2023

Trinder SM; McKay C; Power P; Topp M; Chan B; Valvi S; McCowage G; Govender D; Kirby M; Ziegler DS; Manoharan N; Hassall T; Kellie S; Heath J; Alvaro F; Wood P; Laughton S; Tsui K; Dodgshun A; Eisenstat DD; Endersby R; Luen SJ; Koh ES; Sim HW; Kong B; Gottardo NG; Whittle JR; Khuong-Quang DA; Hansford JR, 2023, 'BRAF-mediated brain tumors in adults and children: A review and the Australian and New Zealand experience', Frontiers in Oncology, 13,

Journal articles | 2023

Wei JQ; Yuile A; Itchins M; Kong BY; Li BT; Pavlakis N; Chan DL; Clarke SJ, 2023, 'Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis', Biomedicines, 11,

Journal articles | 2022

Halkett GKB; Breen LJ; Berg M; Sampson R; Sim HW; Gan HK; Kong BY; Nowak AK; Day BW; Harrup R; James M; Saran F; Mcfarlane B; Tse C; Koh ES, 2022, 'Determining the Research Priorities for Adult Primary Brain Tumours in Australia and New Zealand: A Delphi Study with Consumers, Health Professionals, and Researchers', Current Oncology, 29, pp. 9928 - 9955,

Journal articles | 2022

Kong BY; Carter C; Nowak AK; Hovey E; Lwin Z; Haghighi N; Gan HK; Sim HW; Ziegler DS; Barton K; Parkinson J; Leonard R; Khasraw M; Foote M, 2022, 'Barriers and potential solutions to international collaboration in neuro-oncology clinical trials: Challenges from the Australian perspective', Asia Pacific Journal of Clinical Oncology, 18, pp. 259 - 266,

Journal articles | 2022

Kong BY; Sim HW; Barnes EH; Nowak AK; Hovey EJ; Jeffree R; Harrup R; Parkinson J; Gan HK; Pinkham MB; Yip S; Hall M; Tu E; Carter C; Koh ES; Lwin Z; Dowling A; Simes JS; Gedye C, 2022, 'Multi-Arm GlioblastoMa Australasia (MAGMA): Protocol for a multiarm randomised clinical trial for people affected by glioblastoma', BMJ Open, 12,

Journal articles | 2021

Kong B; Sim H-W; Amanuel B; Day B; Buckland M; Verhaak R; Yip S; Johns T; Lwin Z; Rosenthal M; Nowak AK; Barnes EH; Scott AM; Parkinson J; Jeffree R; De Abreu Lourenco R; Lau P; Whittle J; Hovey E; Cher L; Kichendasse G; Hall M; Robinson C; Thomas M; Giardina T; Tu E; Khasraw M; Koh E-S; Gan H, 2021, 'INNV-08. LOW AND INTERMEDIATE GRADE GLIOMA UMBRELLA STUDY OF MOLECULAR GUIDED THERAPIES (LUMOS) STUDY', Neuro-Oncology, 23, pp. vi106 - vi107,

Journal articles | 2021

Kong B; Sim H-W; Koh E-S; Gan H; Barnes EH; Yip S; Nowak AK; Lau P; Cuff K; Khoo E; Lwin Z; Cooper A; Dowling A; Linton A; Harrup R; Dunlop T; Hovey E; Parkinson J; Jeffree R; Hall M; Tu E; Andrew D; Simes J; Gedye C, 2021, 'RTID-05. THE MULTI-ARM GLIOBLASTOMA AUSTRALASIA (MAGMA) TRIAL', Neuro-Oncology, 23, pp. vi193 - vi194,

Journal articles | 2021

Kong BY; Sim HW; Nowak AK; Yip S; Barnes EH; Day BW; Buckland ME; Verhaak R; Johns T; Robinson C; Thomas MA; Giardina T; Lwin Z; Scott AM; Parkinson J; Jeffree R; Lourenco RDA; Hovey EJ; Cher LM; Kichendasse G; Khasraw M; Hall M; Tu E; Amanuel B; Koh ES; Gan HK, 2021, 'LUMOS - Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS at relapse: Protocol for a pilot study', BMJ Open, 11,

Journal articles | 2021

Oh B; Boyle F; Pavlakis N; Clarke S; Eade T; Hruby G; Lamoury G; Carroll S; Morgia M; Kneebone A; Stevens M; Liu W; Corless B; Molloy M; Kong B; Libermann T; Rosenthal D; Back M, 2021, 'The gut microbiome and cancer immunotherapy: Can we use the gut microbiome as a predictive biomarker for clinical response in cancer immunotherapy?', Cancers, 13,

Journal articles | 2020

Fromm PD; Silveira PA; Hsu JL; Papadimitrious MS; Lo TH; Ju X; Kupresanin F; Romano A; Hsu WH; Bryant CE; Kong B; Abadir E; Mekkawy A; M. McGuire H; Groth BFDS; Cunningham I; Newman E; Gibson J; Hogarth PM; Hart DNJ; Clark GJ, 2020, 'Distinguishing human peripheral blood CD16+ myeloid cells based on phenotypic characteristics', Journal of Leukocyte Biology, 107, pp. 323 - 339,

Journal articles | 2019

Bryant CE; Sutherland S; Kong B; Papadimitrious MS; Fromm PD; Hart DNJ, 2019, 'Dendritic cells as cancer therapeutics', Seminars in Cell and Developmental Biology, 86, pp. 77 - 88,

Journal articles | 2019

Kong BY; Bolton H; Kim JW; Silveira PA; Fromm PD; Clark GJ, 2019, 'On the other side: Manipulating the immune checkpoint landscape of dendritic cells to enhance cancer immunotherapy', Frontiers in Oncology, 9,

Journal articles | 2018

Eroglu Z; Zaretsky JM; Hu-Lieskovan S; Kim DW; Algazi A; Johnson DB; Liniker E; Kong B; Munhoz R; Rapisuwon S; Gherardini PF; Chmielowski B; Wang X; Shintaku IP; Wei C; Sosman JA; Joseph RW; Postow MA; Carlino MS; Hwu WJ; Scolyer RA; Messina J; Cochran AJ; Long GV; Ribas A, 2018, 'High response rate to PD-1 blockade in desmoplastic melanomas', Nature, 553, pp. 347 - 350,

Journal articles | 2018

Hsu JL; Bryant CE; Papadimitrious MS; Kong B; Gasiorowski RE; Orellana D; McGuire HM; Groth BFDS; Joshua DE; Ho PJ; Larsen S; Iland HJ; Gibson J; Clark GJ; Fromm PD; Hart DNJ, 2018, 'A blood dendritic cell vaccine for acute myeloid leukemia expands anti-tumor T cell responses at remission', Oncoimmunology, 7,

Journal articles | 2017

Bowyer S; Prithviraj P; Lorigan P; Larkin J; McArthur G; Atkinson V; Millward M; Khou M; Diem S; Ramanujam S; Kong B; Liniker E; Guminski A; Parente P; Andrews MC; Parakh S; Cebon J; Long GV; Carlino MS; Klein O, 2017, 'Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''', British Journal of Cancer, 116, pp. e15,

Journal articles | 2017

Hwang SJE; Kong BY; Chou S; Wakade D; Carlino MS; Fernandez-Penas P, 2017, 'Acute Truncal Lymphedema Secondary to Axillary Metastatic Melanoma Presenting Like Cellulitis', Case Reports in Medicine, 2017,

Journal articles | 2017

Long GV; Atkinson V; Cebon JS; Jameson MB; Fitzharris BM; McNeil CM; Hill AG; Ribas A; Atkins MB; Thompson JA; Hwu WJ; Hodi FS; Menzies AM; Guminski AD; Kefford R; Kong BY; Tamjid B; Srivastava A; Lomax AJ; Islam M; Shu X; Ebbinghaus S; Ibrahim N; Carlino MS, 2017, 'Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial', Lancet Oncology, 18, pp. 1202 - 1210,

Journal articles | 2017

Naidoo J; Wang X; Woo KM; Iyriboz T; Halpenny D; Cunningham J; Chaft JE; Segal NH; Callahan MK; Lesokhin AM; Rosenberg J; Voss MH; Rudin CM; Rizvi H; Hou X; Rodriguez K; Albano M; Gordon RA; Leduc C; Rekhtman N; Harris B; Menzies AM; Guminski AD; Carlino MS; Kong BY; Wolchok JD; Postow MA; Long GV; Hellmann MD, 2017, 'Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy', Journal of Clinical Oncology, 35, pp. 709 - 717,

Journal articles | 2017

Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA, 2017, 'Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in Melanoma', Clinical Cancer Research, 23, pp. 5024 - 5033,

Journal articles | 2016

Bowyer S; Prithviraj P; Lorigan P; Larkin J; McArthur G; Atkinson V; Millward M; Khou M; Diem S; Ramanujam S; Kong B; Liniker E; Guminski A; Parente P; Andrews MC; Parakh S; Cebon J; Long GV; Carlino MS; Klein O, 2016, 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy', British Journal of Cancer, 114, pp. 1084 - 1089,

Journal articles | 2016

Hwang SJE; Carlos G; Wakade D; Byth K; Kong BY; Chou S; Carlino MS; Kefford R; Fernandez-Penas P, 2016, 'Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort', Journal of the American Academy of Dermatology, 74, pp. 455 - 461.e1,

Journal articles | 2016

Kong BY; Carlino MS; Menzies AM, 2016, 'Biology and treatment of BRAF mutant metastatic melanoma', Melanoma Management, 3, pp. 33 - 45,

Journal articles | 2016

Kong BY; Menzies AM; Saunders CAB; Liniker E; Ramanujam S; Guminski A; Kefford RF; Long GV; Carlino MS, 2016, 'Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy', Pigment Cell and Melanoma Research, 29, pp. 572 - 577,

Journal articles | 2016

Kong BY; Micklethwaite KP; Swaminathan S; Kefford RF; Carlino MS, 2016, 'Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma', Melanoma Research, 26, pp. 202 - 204,

Journal articles | 2016

Liniker E; Menzies AM; Kong BY; Cooper A; Ramanujam S; Lo S; Kefford RF; Fogarty GB; Guminski A; Wang TW; Carlino MS; Hong A; Long GV, 2016, 'Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma', Oncoimmunology, 5,

Journal articles | 2015

Liniker E; Kong B; Menzies AM; Cooper A; Ramanujam S; Lo S; Kefford RF; Fogarty GB; Guminski A; Wang TW; Carlino MS; Hong A; Long GV, 2015, 'Safety and Activity of Combined Radiotherapy (RT) and Anti-PD-1 Antibodies (PD-1) in Patients (pts) with Metastatic Melanoma', EUROPEAN JOURNAL OF CANCER, 51, pp. S664 - S664,

Journal articles | 2015

Liniker E; Kong B; Menzies AM; Cooper AJ; Kefford RF; Fogarty GB; Guminski A; Carlino MS; Wang TW; Long GV; Hong A, 2015, 'Safety and Activity of Combined Radiation Therapy (RT) and Anti-PD-1 Antibodies (PD-1) in Patients (pts) With Metastatic Melanoma', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 93, pp. E635 - E635,

Journal articles | 2007

Clarke RJ; Apell HJ; Kong BY, 2007, 'Allosteric effect of ATP on Na+,K+-ATPase Conformational kinetics', Biochemistry, 46, pp. 7034 - 7044,

Journal articles | 2004

Buhagiar KA; Hansen PS; Kong BY; Clarke RJ; Fernandes C; Rasmussen HH, 2004, 'Dietary cholesterol alters Na+/K+ selectivity at intracellular Na+/K+ pump sites in cardiac myocytes', American Journal of Physiology Cell Physiology, 286, pp. C398 - C405,

Journal articles | 2004

Kong BY; Clarke RJ, 2004, 'Identification of Potential Regulatory Sites of the Na+,K +-ATPase by Kinetic Analysis', Biochemistry, 43, pp. 2241 - 2250,

Journal articles | 2002

Hansen PS; Buhagiar KA; Kong BY; Clarke RJ; Gray DF; Rasmussen HH, 2002, 'Dependence of Na+-K+ pump current-voltage relationship on intracellular Na+, K+, and Cs+ in rabbit cardiac myocytes', American Journal of Physiology Cell Physiology, 283, pp. C1511 - C1521,
Conference Papers | 2025

Brown LJ; Yeo N; Gee H; Kong BY; Hau E; da Silva IP; Nagrial A, 2025, 'Immune Checkpoint Inhibitors +/− Chemotherapy for Patients With NSCLC and Brain Metastases: A Systematic Review and Network Meta-Analysis', in Thoracic Cancer,

Conference Papers | 2023

Sim HW; Wachsmuth L; Barnes EH; Yip S; Koh ES; Hall M; Jennens R; Ashley DM; Verhaak RG; Heimberger AB; Rosenthal MA; Hovey EJ; Ellingson BM; Tognela A; Gan HK; Wheeler H; Back M; Mcdonald KL; Long A; Cuff K; Begbie S; Gedye C; Mislang A; Le H; Johnson MO; Kong BY; Simes JR; Lwin Z; Khasraw M, 2023, 'NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma', in Neuro Oncology Advances,

Conference Papers | 2021

Kong B; Sim H-W; Amanuel B; Day B; Buckland M; Verhaak R; Yip S; Johns T; Lwin Z; Rosenthal M; Nowak AK; Barnes EH; Scott AM; Parkinson J; Jeffree R; Lourenco RDA; Lau P; Whittle J; Hovey E; Cher L; Kichendasse G; Hall M; Robinson C; Thomas M; Giardina T; Tu E; Khasraw M; Koh E-S; Gan H, 2021, 'LOW AND INTERMEDIATE GRADE GLIOMA UMBRELLA STUDY OF MOLECULAR GUIDED THERAPIES (LUMOS) STUDY', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, MA, Boston, pp. 106 - 106, presented at 26th Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO), MA, Boston, 18 November 2021 - 21 November 2021,

Conference Papers | 2021

Kong B; Sim H-W; Koh E-S; Gan H; Barnes EH; Yip S; Nowak AK; Lau P; Cuff K; Khoo E; Lwin Z; Cooper A; Dowling A; Linton A; Harrup R; Dunlop T; Hovey E; Parkinson J; Jeffree R; Hall M; Tu E; Andrew D; Simes J; Gedye C, 2021, 'THE MULTI-ARM GLIOBLASTOMA AUSTRALASIA (MAGMA) TRIAL', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, MA, Boston, pp. 193 - 194, presented at 26th Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO), MA, Boston, 18 November 2021 - 21 November 2021

Conference Papers | 2019

Sutherland S; Abadir E; Kong B; Stockler M; Mahon K; Silveira P; Horvath L; Clark G, 2019, 'Novel Targets for an In Vivo DC Anti-Prostate Cancer Vaccine', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 64 - 65,

Conference Papers | 2018

Kim J; Kong B; Lo T-H; Papadimitrous MS; Hsu J; Fromm P; Kaufman K; Buckland M; Clark G; Hart D, 2018, 'A COMBINATORY IMMUNOTHERAPY AGAINST BRAIN TUMOUR: BLOOD DENDRITIC CELL BASED VACCINE THERAPY WITH CHECKPOINT INHIBITOR(S)', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, LA, New Orleans, pp. 94 - 95, presented at 23rd Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO) / 3rd CNS Anticancer Drug Discovery and Development Conference, LA, New Orleans, 14 November 2018 - 18 November 2018,

Conference Papers | 2018

Kong B; Kim J; Fromm P; Bui KT; Linton A; Kaufman K; Beale P; Buckland M; Clark G, 2018, 'THE IMMUNE LANDSCAPE OF BLOOD DENDRITIC CELLS IN GLIOBLASTOMA MULTIFORME: IMPLICATIONS FOR DC VACCINATION COMBINED WITH CHECKPOINT INHIBITION', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, LA, New Orleans, pp. 132 - 132, presented at 23rd Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO) / 3rd CNS Anticancer Drug Discovery and Development Conference, LA, New Orleans, 14 November 2018 - 18 November 2018,

Conference Papers | 2016

Hwang SJE; Park J; Wakade D; Byth K; Chou S; Kong BY; Carlino MS; Fernandez-Penas P, 2016, 'Cutaneous toxicities of anti-programmed cell death1 antibodies combined with anti-cytotoxic T-lymphocyte-associated protein 4 use in metastatic melanoma patients', in AUSTRALASIAN JOURNAL OF DERMATOLOGY, WILEY-BLACKWELL, pp. 10 - 10,

Conference Papers | 2015

Kong BY; Saunders CAB; Liniker E; Ramanujam S; Kefford RF; Guminski A; Menzies AM; Long GV; Carlino MS, 2015, 'FDG-PET METABOLIC ACTIVITY IN METASTATIC MELANOMA AFTER LONG-TERM TREATMENT WITH ANTI-PD-1 ANTIBODIES', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 40 - 40,

2022/MRF2023943 - Supporting Australian Brain Cancer Research with an integrated network of platforms (Associate Investigator)

2021/MRF2015365��- LUMOS: Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided TherapieS (Associate Investigator)

��

Predictive factor in treatment sequencing for lung cancer brain metastases treated with immunotherapy

Radiomic biomarkers of response in brain metastases

Biomarkers of response to immunotherapy and precision medicine based approaches to lung cancer

Development of brain cancer clinical trials and translational research

91ɫ��Ƭ

Follow

Dr Ben Kong

Follow me